Xlife Sciences AG (SWX:XLS)
Switzerland · Delayed Price · Currency is CHF 20.40
-0.40 (-1.92%)
At close: Oct 21, 2025
Xlife Sciences AG Revenue
Xlife Sciences AG had revenue of 354.32K CHF in the half year ending June 30, 2025, with 1.82% growth. This brings the company's revenue in the last twelve months to 839.38K, down -15.24% year-over-year. In the year 2024, Xlife Sciences AG had annual revenue of 834.88K, down -15.54%.
Revenue (ttm)
839.38K
Revenue Growth
-15.24%
P/S Ratio
140.17
Revenue / Employee
49.38K
Employees
17
Market Cap
117.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 834.88K | -153.56K | -15.54% |
| Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
| Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
| Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
| Dec 31, 2020 | 396.81K | -118.02K | -22.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 43.89B |
| Sandoz Group AG | 8.42B |
| Alcon | 7.97B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.87B |
| Galderma Group AG | 3.73B |